The 8 most recent market catalysts affecting $CANF, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
Can Fite Biofarma (CANF) reported a quarterly loss of $(1.24) per share, which was better than the analyst consensus estimate of $(1.43). This represents a significant improvement …
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 85
Can-Fite BioPharma Says Blinded Overall Survival In Pivotal Phase 3 Namodenoson Liver Cancer Study Appears Longer Than Originally Anticipated; Evaluating Earlier Timing For Planned Interim Analysis
The headline indicates that Can-Fite BioPharma's Namodenoson, a drug for liver cancer, is showing better-than-expected overall survival in its pivotal Phase 3 study. This 'blinded'…
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 75
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Can-Fite BioPharma announced two significant developments. First, the company is considering an earlier interim analysis for its pivotal Phase 3 liver cancer trial due to observed …
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 85
Can-Fite BioPharma shares are trading lower after the company said blinded overall survival in its Phase III Namodenoson study for advanced HCC appears longer than expected under the trial design assumptions.
The headline indicates a significant negative catalyst for Can-Fite BioPharma. While longer overall survival might sound good, in a blinded trial, it implies that the placebo group…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 75
Can-Fite Plans To Advance Interim Analysis Of Phase III Namodenoson Study In Advanced Hepatocellular Carcinoma
This headline represents a significant corporate catalyst for Can-Fite BioPharma. Advancing an interim analysis suggests either strong preliminary data or a strategic move to exped…
Aug 17, 2026
Corporate Catalyst
Neutral
Impact 65
Can-Fite BioPharma Announces New Preclinical Findings Demonstrating Namodenoson Enhances Anti-Cancer Effect Of Gemcitabine Chemotherapy In Pancreatic Cancer
Can-Fite BioPharma (CANF) announced new preclinical findings demonstrating that its drug, namodenoson, enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic can…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 65
Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe Syndrome
Can-Fite BioPharma announced the submission of a Phase 2 clinical study protocol for Piclidenoson in Lowe syndrome, a rare genetic disorder with no current treatments. This is sign…
Jul 20, 2026
Corporate Catalyst
Neutral
Impact 65
Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The Event
Can-Fite BioPharma (CANF) announced that an abstract detailing positive results from its Phase 2a study of Namodenoson in advanced pancreatic cancer has been accepted for poster pr…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.